Skip to search formSkip to main contentSkip to account menu

BMS-207147

National Institutes of Health

Related topics

Related topics

2 relations
ER 30346

Broader (1)

ravuconazole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.
Ravuconazole (BMS-207147, ER-30346), an oral triazole, was evaluated in an immunosuppressed temporarily neutropenic guinea pig… 
Highly Cited
2001
Highly Cited
2001
Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative Evaluation
ABSTRACT The most important role of susceptibility testing is to identify potentially resistant isolates for the agent being… 
Highly Cited
2000
Highly Cited
2000
In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans
ABSTRACT The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and… 
Highly Cited
2000
Highly Cited
2000
In Vitro Activity of the New Triazole BMS-207147 againstAspergillus Species in Comparison with Itraconazole and Amphotericin B
ABSTRACT The in vitro activity of BMS-207147 against 80 clinical isolates ofAspergillus was compared with that of itraconazole… 
Review
2000
Review
2000
New agents for treatment of systemic fungal infections
Systemic antifungal chemotherapy is enjoying its most dynamic era. More antifungal agents are under development than ever before… 
Highly Cited
1999
Highly Cited
1999
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole…
1999
1999
In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
ABSTRACT We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole… 
1999
1999
In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.
Highly Cited
1998
Highly Cited
1998
In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
ABSTRACT The antifungal activity of BMS-207147 (also known as ER-30346) was compared to those of itraconazole and fluconazole… 
Highly Cited
1998
Highly Cited
1998
In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
ABSTRACT BMS-207147, Sch 56592, and voriconazole are three new investigational triazoles with broad-spectrum antifungal activity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)